| |
|
Inpatient group
(n=172) |
Outpatient group
(n=55) |
P-value |
Total
(n=227) |
| Sex |
Male |
132 (77%) |
42 (76%) |
0.954 |
174 (77%) |
| Age |
Mean in years (±SD) |
57.3 (±7.6) |
57.8 (±8.3) |
0.655 |
57.4 (±7.8) |
| Tobacco Status |
Current smoker |
91 (53%) |
15 (31%) |
0.005 |
106 (48%) |
| Former and never smoker |
80 (47%) |
34 (69%) |
114 (52%) |
| Missing |
1 |
6+ |
|
7 |
| Size |
Mean in cm(±SD) |
170 (±9) |
169 (±6) |
0.711 |
170 (±8) |
| Missing |
1 |
1 |
|
2 |
| Weight at diagnosis |
Mean in Kg (±SD) |
69 (±13) |
69 (±11) |
0.708 |
69 (±13) |
| Missing |
3 |
5 |
|
8 |
| Histologic subtype |
Adenocarcinoma |
102 (60%) |
30 (54%) |
0.695 |
132 (58%) |
| Squamous cell carcinoma |
40 (23%) |
13 (24%) |
53 (24%) |
| Other |
29 (17%) |
12 (22%) |
41 (18%) |
| Missing |
1 |
|
|
1 |
| Disease stage |
Stage I to IIIA |
27 (16%) |
11 (20%) |
0.468 |
38 (17%) |
| Stage IIIB and IV |
144 (84%) |
44 (80%) |
|
188 (83%) |
| Missing |
1 |
|
|
1 |
| Performance status |
PS 0 to 1 |
159 (95%) |
47 (94%) |
0.547 |
206 (95%) |
| PS 2 |
9 (5%) |
3 (6%) |
|
12 (5%) |
| Missing |
4 |
5 |
|
9 |
| Chemotherapy doublet drug |
Docetaxel |
2 (1%) |
30 (54%) |
<0.0001 |
32 (14%) |
| Gemcitabine |
79 (46%) |
19 (35%) |
98 (43%) |
| Pemetrexed |
24 (14%) |
5 (9%) |
29 (13%) |
| Vepeside |
1 (1%) |
- |
1 (1%) |
| Vinorelbine |
65 (38%) |
1 (2%) |
66 (29%) |
| Bevacizumab |
10 (6%) |
0 |
0.124 |
10 (4.4%) |
| Scheme with day-8 |
142 (83%) |
20 (36%) |
<0.0001 |
162 (72%) |
| Missing |
1 |
- |
|
1 |
| Thoracic radiotherapy |
Yes |
37 (25%) |
11 (22%) |
0.702 |
48 (24%) |
| Missing |
22 |
5 |
|
27 |
| Cisplatin planned delivery dose |
Median in mg/m² (±IQR) - |
80 (±0) |
75 (±5) |
<0.0001 |
80 (±5) |
| Missing |
7 |
3 |
|
10 |
| Cisplatin delivered courses (n=226) |
Median ±IQR |
4 (±3) |
4 (±2) |
0.065 |
4 (±3) |
| Missing |
|
|
|
|
| Relevant comorbiditiesa |
At least one |
47 (27%) |
12 (22%) |
0.405 |
59 (26%) |
| Missing |
1 |
|
|
1 |
| Concomitant use of nephrotoxic drugsb |
At least one |
34 (20%) |
4 (7%) |
0.03 |
38 (17%) |
| Missing |
1 |
|
|
1 |
|
